Citius Oncology, Inc. Receives Nasdaq Non-Compliance Notice over Minimum Bid Price Rule

Key Developments Investors Need to Know

Citius Oncology, Inc. (Nasdaq: CTOR) has disclosed a significant regulatory update that could have material implications for shareholders and the company’s stock price. On April 22, 2026, the company received an official notification from the Nasdaq Stock Market LLC (“Nasdaq”) indicating that its common stock has failed to meet the minimum bid price requirement of \$1.00 per share, as stipulated by Nasdaq Listing Rule 5550(a)(2), for the past 30 consecutive business days.

Summary of the Nasdaq Notification

• Minimum Bid Price Deficiency: Citius Oncology’s common stock has closed below the required \$1.00 minimum bid price for 30 consecutive business days.
• Initial Compliance Period: The company has been granted a grace period of 180 calendar days, until October 19, 2026, to regain compliance with the minimum bid price rule.
• Compliance Criteria: To cure the deficiency, the company’s stock must close at or above \$1.00 per share for at least ten consecutive business days within the compliance period.
• Potential Extension: If Citius Oncology fails to regain compliance by October 19, 2026, but meets all other continued listing requirements (except for the bid price rule), it may be eligible for an additional 180-day extension. The company must also provide a written notice of its intention to cure the deficiency, potentially by enacting a reverse stock split.
• Risk of Delisting: Should the company fail to regain compliance within the allotted timeframes, Nasdaq will issue a written notice of delisting. The company would then have the right to appeal the decision before a Nasdaq hearings panel.
• Current Status: The notification does not have any immediate effect on the trading of Citius Oncology’s common stock, which will continue to trade on the Nasdaq Capital Market under the symbol “CTOR.”
• Company Response: Management is currently evaluating its options for regaining compliance. However, there is no assurance that the company will succeed in curing the deficiency or maintain compliance with other Nasdaq listing standards.

Implications for Shareholders

This development is price sensitive and could have significant implications for shareholders. Non-compliance with Nasdaq listing standards, particularly the minimum bid price rule, typically exerts downward pressure on a company’s share price due to concerns over potential delisting, reduced liquidity, and diminished investor confidence.

If Citius Oncology fails to regain compliance, potential outcomes include:

• A reverse stock split to increase the per-share price.
• Delisting from the Nasdaq Capital Market, which would move the stock to an over-the-counter (OTC) market, likely resulting in reduced liquidity and increased trading volatility.
• Further challenges in accessing capital markets or attracting institutional investors.

The company is classified as an Emerging Growth Company under SEC rules. This status may provide certain regulatory and reporting relief, but it does not diminish the seriousness of the Nasdaq compliance issue.

Key Facts for Investors

• Issuer: Citius Oncology, Inc.
• Trading Symbol: CTOR
• Exchange: Nasdaq Capital Market
• Notification Received: April 22, 2026
• Initial Compliance Deadline: October 19, 2026
• Potential for Additional Compliance Period: Yes, subject to meeting other listing standards
• Immediate Effect on Trading: None; stock remains on Nasdaq pending compliance efforts

What Should Shareholders Do?

Shareholders should closely monitor company updates regarding compliance efforts, including any announcements of a reverse stock split or other corporate actions. The risk of delisting remains until the company demonstrates compliance with the Nasdaq minimum bid price rule. Investors should consider their risk tolerance and consult with financial advisors regarding the potential impact on their holdings.

Disclaimer

This article is for informational purposes only and does not constitute financial advice or a recommendation to buy or sell securities. Investors should conduct their own due diligence and consult with a qualified financial advisor before making investment decisions. The information in this article is based on the company’s public SEC filings and is subject to change without notice.

View CITIUS ONCOLOGY, INC. Historical chart here